PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16735966-5 2006 RESULTS: 5"-nucleotidase activity in diabetic patients before treatment with gliclazide was 1.61 +/- 0.16 nmol/min/10(6) lymphocytes, and was significantly (P < 0.01) increased compared with the level in healthy controls. Gliclazide 77-87 5'-nucleotidase ecto Homo sapiens 9-24 16735966-0 2006 Lymphocyte ecto-5"-nucleotidase in obese type 2 diabetic patients treated with gliclazide. Gliclazide 79-89 5'-nucleotidase ecto Homo sapiens 11-31 16735966-2 2006 The aim of this study was to assess the effect of the sulfonylurea drugs gliclazide and glibenclamide on lymphocyte ecto-5"-nucleotidase of type 2 diabetic patients. Gliclazide 73-83 5'-nucleotidase ecto Homo sapiens 116-136 16735966-6 2006 After three months of gliclazide treatment, ecto-5"-nucleotidase activity fell significantly by 47.39% and 36% in unstimulated Con A- and PMA-stimulated lymphocytes, respectively. Gliclazide 22-32 5'-nucleotidase ecto Homo sapiens 44-64 16735966-10 2006 CONCLUSION: These results show that gliclazide treatment inhibits the activity of lymphocyte ecto-5"-nucleotidase and presumably de-creases the concentration of adenosine at the cell surface. Gliclazide 36-46 5'-nucleotidase ecto Homo sapiens 93-113